Introduction {#s0001}
============

The number of patients on hemodialysis (HD) is increasing, and they have a high mortality rate \[[@CIT0001]\], which is mainly a result of the presence of cardiovascular disease that is not completely explained by the presence of traditional risk factors \[[@CIT0002]\]. HD patients often develop systemic mineral and bone metabolism disorders that involve biochemical and bone abnormalities, and vascular calcification \[[@CIT0003]\]. These abnormalities are prevalent and represent nontraditional risk factors \[[@CIT0006]\].

Most patients who undergo HD have vitamin D deficiencies, which can be influenced by age, skin pigmentation, the duration of exposure to the sun, obesity, the use of sunscreen, and the presence of diseases, including diabetes mellitus and chronic kidney disease (CKD) \[[@CIT0007],[@CIT0008]\]. Up to 90% of HD patients can be vitamin D deficient, and this is associated with increased arterial stiffness, increases in the prevalence of vascular calcification, stroke, and left ventricular hypertrophy, and greater risks of all-cause death and cardiovascular mortality \[[@CIT0002],[@CIT0009]\].

The findings from several observational studies have shown that low vitamin D levels are associated with all-cause mortality in HD patients \[[@CIT0010],[@CIT0011]\]. A meta-analysis of prospective observational studies showed a reduced risk of mortality among patients with chronic renal disease and higher vitamin D levels, regardless of the disease stage \[[@CIT0012]\].

Controversy exists regarding the optimal vitamin D level, and specific vitamin D levels for patient populations with and without CKD have not been defined \[[@CIT0013]\]. The ideal serum 25-hydroxyvitamin D (25\[OH\]D) levels in patient populations should be stratified according to age and individual clinical characteristics. A serum 25(OH)D concentration \>20 ng/mL is the reference level for healthy individuals ≤60 years old, and a concentration of 30--60 ng/mL is recommended for older adults, pregnant or lactating women, and for patients with rickets/osteomalacia, osteoporosis or secondary causes of osteoporosis, hyperparathyroidism, inflammatory diseases, autoimmune diseases, CKD, malabsorption syndromes, and patients with histories of falls and fractures \[[@CIT0007]\].

The current CKD guidelines \[[@CIT0014],[@CIT0015]\] recommend that, regardless of the CKD stage, 25(OH)D levels should be maintained at \>30 ng/mL. However, the 25(OH)D level below which higher mortality rates occur in HD patients remains unclear. Thus, the objective of this study was to identify the serum 25(OH)D cutoff value below which mortality increases in HD patients.

Methods {#s0002}
=======

This unicentric cohort study enrolled patients who underwent HD from January 2014 to January 2017. The primary outcome was all-cause death, and the secondary outcome was death from cardiovascular causes. The end of follow-up was defined as death by any cause, withdraw of follow-up, or if do not reach any of these outcomes, followed until January/2017. This study was approved by the local research ethics committee (Approval number: 1622148), and the requirement for informed consent was waived because it was a retrospective study and it followed the Strengthening the Reporting of Observational Studies in Epidemiology Guidelines \[[@CIT0016]\].

The variable of interest was the serum 25(OH)D level, which was measured by chemiluminescence immunoassay and evaluated every 6 months before the second session of hemodialysis, after 6 h of fasting, in the first weeks of January and July that represented summer and winter, respectively, in the southern hemisphere. The other variables evaluated included age, sex, race, body mass index (BMI), baseline diseases, arterial hypertension (characterized by sustained rise in blood pressure ≥ 140 and/or 90 mmHg), diabetes mellitus, atherosclerotic disease (encephalic vascular accident, coronary artery disease, and peripheral obstructive arterial disease), the time on HD, which was defined as the time from the onset of therapy to the first measurement of the serum 25(OH)D level, smoking, the arterial blood pressure, the laboratory test results, the use of calcitriol during the first year of follow-up, inhibitors of the renin-angiotensin system (RAS), statin, and antiplatelet drugs use, the fractional clearance of urea, and the vascular access type. The variables were analyzed according to the season, namely, summer, winter, and annual average, and the patients were compared in relation to all-cause death. The 25(OH)D levels were categorized into quintiles, because of the nonlinear associations with the outcomes.

HD patients were included if they were \>18 years of age and had ≥1 laboratory test result for the serum 25(OH)D level. The exclusion criteria were a history of malignant neoplasms, parathyroidectomy, or hepatic cirrhosis, and patients who had undergone HD for \<1 month.

Statistical analyses {#s0003}
--------------------

The data from the variables with normal distributions are expressed as the means and the standard deviations, and the data from the variables with nonnormal distributions are expressed as the medians and interquartile ranges. The frequencies are presented as percentages. Comparisons of the normally distributed data were performed using Student's *t*-test, and comparisons of the nonnormally distributed data were performed using the Mann-Whitney test. The chi-squared test was used to analyze the categorical variables. Statistical inferences related to associations between the serum 25(OH)D levels and the outcomes were analyzed using multivariate Cox proportional hazards regression analyses. The variables that were associated with the outcomes at a level of significance of *p* \< 0.1 in the univariate analysis were selected for the multivariate analysis. Gender, ethnicity, BMI, and medication use were forced into the model, because of the prognostic relevance of these variables. To assess the proportionality of the hazards in the Cox proportional hazards regression model, the Schoenfeld test was performed. A value of *p* \< 0.05 was considered statistically significant. All of the statistical analyses were performed using IBM^®^SPSS^®^ software, version 20.0 for Windows (IBM Corporation, Armonk, NY, USA).

Results {#s0004}
=======

[Figure 1](#F0001){ref-type="fig"} shows a flowchart of the patients' inclusion in the study. No differences were evident between the patients who died or survived in relation to sex, race, BMI, and the type of vascular access. Statistically significant differences were evident between the patients who died or survived in relation to age, arterial hypertension, diabetes mellitus, atherosclerotic disease, HD vintage, and statin use ([Table 1](#t0001){ref-type="table"}).

![Study flowchart.](IRNF_A_1735415_F0001_B){#F0001}

###### 

Clinical characteristics of the patients on hemodialysis who survived or died.

                                             Total              Survivors          Nonsurvivors        *p* Value
  ------------------------------------------ ------------------ ------------------ ------------------- -----------
  Age^+^ (years); mean (SD)                  58 ± 15.0          56 ± 15.2          65 ± 12.3           \<0.001
  Sex\* (%)                                                                                            
   Female                                    47                 47                 47                  0.917
   Male                                      53                 53                 53                  
  Ethnicity\* (%)                                                                                      
   White                                     74                 72                 77                  0.533
   Mixed race                                19                 20                 19                  
   Black                                     7                  8                  4                   
  CKD etiology\* (%)                                                                                   
   Arterial hypertension                     20                 21                 18                  0.705
   Diabetes                                  35                 32                 45                  
   Glomerular disease                        11                 13                 4                   
   Urological disease                        6                  6.0                7                   
   Indeterminate                             9                  10                 6                   
   Other causes^a^                           19                 18                 20                  
  Comorbidity\* (%)                                                                                    
   Arterial hypertension                     82                 78                 93                  0.006
   Diabetes                                  47                 42                 60                  0.012
   Smoker                                    40                 40                 38                  0.868
   Atherosclerotic disease                   39                 33                 38                  \<0.001
   Other^b^                                  53                 52                 56                  0.619
  Median hemodialysis vintage\*\* (months)   5.3 (2.3 − 26.8)   4.6 (2.0 − 21.1)   18.4 (3.8 − 33.4)   \<0.001
  Median follow-up duration (months)         18 (1 − 37)        18.6 (1 − 37)      13.6(1 − 36)        --
  Weight (Kg)^+^                             67.9 ± 15.91       68.4 ± 15.64       66.2 ± 16.72        0.298
  Dry weight (Kg)^+^                         67.0 ± 15.84       67.6 ± 15.48       65.0 ± 16.94        0.231
  Height (cm)^+^                             161 ± 9.8          161 ± 9.8          161 ± 9.87          0.713
  BMI (kg/m^2^)^+^                           25.9 ± 5.36        26.1 ± 5.26        25.3 ± 5.71         0.305
  Vascular access (%)\*                                                                                
   Nontunneled catheter                      8                  6                  14                  0.900
   Tunneled catheter                         58                 57                 60                  
   Arteriovenous fistula                     34                 36                 26                  
  Drugs use\*                                                                                          
   Antiplatelet drugs                        183                132                51                  0.061
   Statins                                   203                146                57                  0.020
   RAS inhibitors                            129                96                 33                  0.639

SD: standard deviation; CKD: chronic kidney disease, RAS: renin-angiotensin system, BMI: body mass index. \*Chi-squared test; ^+^*t*-test; \*\*Mann--Whitney test.

^a^Other causes: ischemic nephropathy, polycystic kidney disease, acute renal injury, loss of renal graft, Alport's syndrome, renal cystinosis; atherosclerotic disease: vascular accident encephalic, coronary artery disease, and peripheral obstructive arterial disease.

^b^Other comorbidities: dyslipidemia, hypothyroidism, obesity, cardiac arrhythmia, hyperuricemia, neurological, and others.

The number of vitamin D samples analyzed were from one per season (one in winter and one in summer) (only 76 patients) to four per season. The median of the number of repetitions was two per season. When there was more than one sample per season the vitamin D was averaged. The median time of follow-up was 18 months, from one to 36 months.

Regarding the laboratory test results ([Table 2](#t0002){ref-type="table"}), the survivors and nonsurvivors differed in relation to the 25(OH)D and C-reactive protein levels in summer and winter, and they differed regarding the phosphorus and parathyroid hormone levels in winter. Of the 306 HD patients who participated in this study, 73 patients died. The main causes of death were infection (49.3%), cardiovascular (28.8%), undetermined (9.6%), and other (12.3%).

###### 

Laboratory characteristics of the hemodialysis patients in summer and winter who survived or died.

  Summer                                                                                                 
  --------------------------------------- -------------------- -------------------- -------------------- ---------
  Vitamin D (ng/mL); mean (SD)            27.6 ± 11.00         28.9 ± 10.88         23.3 ± 10.32         \<0.001
  Calcium (mg/dL); mean (SD)              8.7 ± 1.87           8.8 ± 1.76           8.6 ± 2.19           0.619
  Phosphorus (mg/dL); mean (SD)           5.4 ± 1.72           5.4 ± 1.67           5.2 ± 1.88           0.363
  PTH (pg/mL); median (range)             321 (188 − 569)      330 (197 − 582)      287 (135 − 526)      0.293
  Albumin (g/dL); mean (SD)               3.9 ± 0.44           3.9 ± 0.45           3.9 ± 0.39           0.266
  Phosphatase (µg/L); median (range)      111 (86 − 149)       110 (84 − 147)       112 (93 − 157)       0.272
  CRP (mg/dL); median (range)             1.19 (0.70 − 2.10)   1.10 (0.67 − 2.00)   1.60 (0.90 − 3.07)   \<0.001
  Hemoglobin (g/dL); mean (SD)            11.5 ± 1.44          11.6 ± 1.48          11.4 ± 1.33          0.507
  Ferritin (ng/mL); mean (SD)             801.5 ± 716.9        730.7 ± 671.9        872.4 ± 761.9        0.178
  Iron (mcg/dL); mean (SD)                77.2 ± 36.7          78.2 ± 28.9          76.2 ± 44.6          0.700
  Transferrin saturation (%); mean (SD)   35.4 ± 15.7          35.7 ± 13.0          35.1 ± 18.4          0.775
  Pre-urea (mg/dL); mean (SD)             109.6 ± 30.5         110.3 ± 31.7         109 ± 29.3           0.784
  Post-urea (mg/dL); mean (SD)            32.6 ± 12.8          33.1 ± 12.9          32.1 ± 12.8          0.603
  URR; mean (SD)                          0.70 ± 0.07          0.70 ± 0.07          0.70 ± 0.08          0.543
  Kt/V; mean (SD)                         1.26 ± 0.35          1.24 ± 0.30          1.29 ± 0.40          0.313

  Winter                                                                                                       
  --------------------------------------------- -------------------- -------------------- -------------------- ---------
  Vitamin D (ng/mL); mean (SD)                  25.5 ± 8.95          26.3 ± 9.18          23.3 ± 7.89          0.024
  Calcium (mg/dL); mean (SD)                    9.1 ± 0.86           9.0 ± 0.90           9.2 ± 0.71           0.309
  Phosphorus (mg/dL); mean (SD)                 5.2 ± 1.81           5.4 ± 1.38           4.5 ± 2.51           \<0.001
  PTH hormone (pg/mL); median (range)           284 (154 − 495)      317 (179 − 566)      250 (102 − 504)      0.047
  Albumin (g/dL); mean (SD)                     3.9 ± 0.42           3.9 ± 0.41           3.8 ± 0.43           0.134
  alkaline phosphatase (µg/L); median (range)   118 (90 − 153)       118 (88 − 154)       119 (94 − 153)       0.838
  CRP (mg/dL); median (range)                   1.60 (1.00 − 2.80)   1.50 (0.90 − 2.70)   2.15 (1.25 − 3.55)   0.009
  Hemoglobin (g/dL); mean (SD)                  11.3 ± 1.63          11.3 ± 1.40          11.3 ± 2.21          0.855
  Ferritin (ng/mL); mean (SD)                   793.8 ± 658.6        744.9 ± 636.5        842.8 ± 680.7        0.365
  Iron (mcg/dL); mean (SD)                      81.4 ± 30.7          81.5 ± 34.6          81.3 ± 26.9          0.962
  Transferrin saturation (%); mean (SD)         35.5 ± 13.9          35.2 ± 13.8          35.8 ± 14.0          0.792
  Pre-urea (mg/dL); mean (SD)                   111.4 ± 28           114.6 ± 27.5         108.3 ± 28.6         0.169
  Post-urea (mg/dL); mean (SD)                  35.5 ± 14            35.6 ± 12            35.4 ± 16            0.914
  URR; mean (SD)                                0.67 ± 0.08          0.68 ± 0.06          0.67 ± 0.10          0.302
  Kt/V; mean (SD)                               1.17 ± 0.23          1.18 ± 0.19          1.16 ± 0.27          0.561

SD: standard deviation; PTH: parathyroid hormone; CRP: C-reactive protein; URR: urea reduction ratio; Kt/V: fractional clearance of urea.

For the survival analysis, the patients were assigned to quintiles according to their serum 25(OH)D levels in the summer (first quintile: ≤18.0 ng/mL; second quintile: \>18.0--≤23.6 ng/mL; third quintile: \>23.6--≤30.3 ng/mL; fourth quintile: \>30.3--36.3 ng/mL; and fifth quintile: \>36.3 ng/mL), winter (first quintile: ≤17.5 ng/mL; second quintile: \>17.5--≤21.5 ng/mL; third quintile: \>21.5--≤27.1 ng/mL; fourth quintile: \>27.1--32.6 ng/mL; and fifth quintile: \>32.6 ng/mL), and annual average (first quintile: ≤17.7 ng/mL; second quintile: \>17.7--≤23.1 ng/mL; third quintile: \>23.1--≤28.4 ng/mL; fourth quintile: \>28.4-- ≤34.8 ng/mL; and fifth quintile: \>34.8 ng/mL). Twenty-one events relating to cardiovascular mortality occurred that were not associated with vitamin D in either summer or winter.

[Table 3](#t0003){ref-type="table"} presents the associations between the clinical variables evaluated in summer and mortality. We selected variables that were significant in the univariate analysis, and, after adjustments, the presence of diabetes mellitus, age, gender, ethnicity, calcitriol use during the first year of follow-up, antiplatelet drugs use, statin use, RAS inhibitors use, HD vintage, and C-reactive protein were excluded; and BMI, the presence of atherosclerotic disease and hypertension, and the 25(OH)D level remained in the model. The Schoenfeld proportionality was not statistically significant, which validated the use of the Cox regression model for the analysis.

###### 

Cox regression analysis of the associations between the clinical variables in summer and mortality.

                                                   HR      95% CI   *p* Value   
  ------------------------------------------------ ------- -------- ----------- -------
  Step 1                                                                        
   Vitamin D quintile                                                           
   5th quintile: \>36.3 ng/mL                      1.000                         
   4th quintile: \>30.3--≤36.3 ng/mL               2.378   0.829    6.821       0.107
   3rd quintile: \>23.6--≤30.3 ng/mL               1.755   0.540    5.704       0.350
   2nd quintile: \>18.0--≤23.6 ng/mL               4.136   1.391    12.292      0.011
   1st quintile: ≤18.0 ng/mL                       3.761   1.214    11.649      0.022
   Age (years)                                     1.013   0,992    1.034       0.222
   Gender                                          0.752   0.432    1.312       0.316
   Ethnicity                                                                    
    White                                          1.000                         
    Mixed race                                     1.332   0,672    2,642       0.411
    Black                                          0,466   0,136    1,602       0.226
   BMI (kg/m²)                                     0.947   0.899    0.998       0.042
   Antiplatelet drugs use                          0.792   0.440    1.425       0.437
   Statin use                                      1.354   0.711    2.577       0.356
   RAS inhibitors use                              1.053   0.628    1.763       0.846
   Calcitriol use in the first year of follow-up   0.928   0.542    1.588       0.784
   Hemodialysis vintage (months)                   1.002   0.996    1.008       0.533
   Presence of hypertension                        2.466   0.955    6.368       0.062
   Presence of diabetes mellitus                   1.566   0.874    2.807       0.132
   Presence of atherosclerotic disease             1.423   0.834    2.429       0.195
   CRP (mg/dL)                                     1.031   0.972    1.094       0.307
  Step 6                                                                        
   5th quintile: \>36.3 ng/mL                      1.000                         
   4th quintile: \>30.3--≤36.3 ng/mL               2.474   0.885    6.917       0.084
   3rd quintile: \>23.6--≤30.3 ng/mL               1.677   0.544    5.167       0.368
   2nd quintile: \>18.0--≤23.6 ng/mL               4.302   1.603    11.541      0.004
   1st quintile: ≤18.0 ng/mL                       3.834   1.421    10.346      0.008
   BMI (kg/m²)                                     0.952   0.909    0.997       0.035
   Presence of hypertension                        2.922   1.169    7.307       0.022
   Presence of atherosclerotic disease             1.578   0.967    2.573       0.068

CRP: C-reactive protein; HR: hazard ratio; CI, confidence interval. BMI: body mass index; RAS: renin-angiotensin system.

During summer, significant associations were evident between all-cause mortality and the first 25(OH)D quintile (adjusted hazard ratio \[HR\] = 3.83, 95% confidence interval \[95% CI\]: 1.42--10.35, *p* = 0.008), all-cause mortality and the second 25(OH)D quintile (adjusted HR = 4.30, 95% CI: 1.60--11.54, *p* = 0.004), all-cause mortality and BMI (adjusted HR = 0.95, 95% CI: 0.90-0.99, *p* = 0.035), and between all-cause mortality and the presence of arterial hypertension (adjusted HR = 2.92, 95% CI: 1.17--7.30, *p* = 0.022). The presence of atherosclerotic disease was not associated with all-cause mortality (adjusted HR = 1.57, 95% CI: 0.96--2.57, *p* = 0.068).

[Table 4](#t0004){ref-type="table"} presents the associations between the clinical variables and all-cause mortality during winter. In this season, significant association were found between all-cause mortality and the first 25(OH)D quintile (adjusted HR = 2.84, 95% CI: 1.13--7.13, *p* = 0.026), all-cause mortality and the third 25(OH)D quintile (adjusted HR = 3.70, 95% CI: 1.50--9.11, *p* = 0.004). The presence of hypertension was independently associated with all-cause mortality (adjusted HR = 3.59, 95% CI: 1.29--9.97, *p* = 0.014).

###### 

Cox regression analysis of the associations between the clinical variables in winter and mortality.

  ---------------------------------------------------------------------------
                                         HR      95% CI   *p* Value   
  -------------------------------------- ------- -------- ----------- -------
  Step 1                                                              

   Age (years)                           1.020   0.996    1.045       0.100

   Gender                                0.965   0.530    1.758       0.907

   Ethnicity                                                          

    White                                1.000                         

    Mixedrace                            1.765   0.856    3.640       0.124

    Black                                0.427   0.100    1.820       0.250

   Presence of atherosclerotic disease   1.288   0.739    2.245       0.372

   Hemodialysis vintage (months)         1.003   0.994    1.012       0.550

   Presence of hypertension              3.102   1.066    9.027       0.038

   Presence of diabetes mellitus         1.024   0.557    1.882       0.938

   Phosphorus (mg/dL)                    1.150   0.927    1.426       0.203

   PTH hormone (pg/mL)                   0.999   0.998    1.000       0.116

   CRP (mg/dL)                           1.067   0.997    1.142       0.062

   Vitamin D quintiles                                                

    5th \>32.6 ng/mL                     1.000                         

    4th \>27.1-≤32.6ng/mL                1.850   0.675    5.072       0.232

    3rd \>21.5--≤27.1 ng/mL              3.260   1.265    8.401       0.014

    2nd \>17.5--≤21.5 ng/mL              1.688   0.599    4.760       0.322

    1st ≤17.5 ng/mL                      2.793   0.980    7.962       0.055

  Step 7                                                              

   Presence of hypertension              3.591   1.292    9.978       0.014

   PTH\                                  0.999   0.998    1.000       0.096
  Vitamin D quintiles                                                 

    5th \>32.6 ng/mL                     1.000                         

    4th \>27.1-≤32.6ng/mL                1.900   0.704    5.126       0.205

    3rd \>21.5--≤27.1 ng/mL              3.699   1.503    9.106       0.004

    2nd \>17.5--≤21.5 ng/mL              1.831   0.710    4.725       0.211

    1st ≤17.5 ng/mL                      2.841   1.131    7.132       0.026
  ---------------------------------------------------------------------------

PTH: parathyroid hormone; CRP: C-reactive protein; HR: hazard ratio; CI, confidence interval.

As shown in [Table 5](#t0005){ref-type="table"}, regarding the associations between clinical variables and mortality from all causes in the annual average, statistical significance were found between all-cause mortality and the presence of hypertension (adjusted HR = 2.75, 95% CI: 1.10--6.98, *p* = 0.031), between all-cause mortality and the first 25(OH)D quintile; \<17.7 ng/dL (adjusted HR = 4.25, 95% CI: 1.57--11.48, *p* = 0.004), and between \>17.7 ng/dL and ≤23.1 ng/dL (adjusted HR = 3.91, 95% CI: 1.47--10.42, *p* = 0.006).

###### 

Cox regression analysis of the associations between the clinical variables in the annual average and mortality.

                                                   HR          95% CI   *p* Value    
  ------------------------------------------------ ----------- -------- ------------ -------
  Step 1                                                                             
   Age (years)                                     1.022       1.000    1.043        0.049
   Gender                                          1.255       0.722    2.181        0.421
   Ethnicity                                                                         
    White                                          1.000                              
    Mixedrace                                      2.485       0.573    10.778       0.224
    Black                                          3.471       0.719    16.752       0.121
   Presence of atherosclerotic disease             0.715       0.418    1.224        0.222
   Hemodialysis vintage (months)                   0.817       0.651    1.025        0.081
   Presence of hypertension                        2.099       0.812    5.428        0.126
   Presence of diabetes mellitus                   0.744       0.419    1.321        0.312
   Phosphorus (mg/dL)                              3.2 10^3^   0.564    1.83 10^3^   0.067
   PTH hormone (pg/mL)                             1.318       0.529    3.284        0.553
   CRP (mg/dL)                                     0.273       0.066    1.140        0.075
   BMI (kg/m²)                                     0.245       0.059    1.023        0.054
   Antiplatelet drugs use                          4.854       0.998    23.619       0.050
   Statin use                                      2,474       0.509    12.031       0.262
   RAS inhibitors use                              3.373       0.752    15.123       0.112
   Calcitriol use in the first year of follow-up   4.213       0.927    19.157       0.063
   Vitamin D quintiles                                                               
    5th \>34.8 ng/mL                               1.000                              
    4th \>28.4 ≤ 34.8 ng/mL                        2.381       0.832    6.811        0.106
    3rd \>23.1 ≤ 28.4 ng/mL                        1.865       0.603    5.767        0.279
    2nd \> 17.7 ≤ 23.1 ng/mL                       3.540       1.243    10.082       0.018
    1st ≤17.7 ng/mL                                3.801       1.240    11.652       0.019
  Step 7                                                                             
   Age                                             1.018       0.999    1.037        0.065
   Presence of hypertension                        2.755       1.097    6.981        0.031
   BMI (kg/m²)                                     0.956       0.913    1.001        0.056
   Vitamin D quintiles                                                               
    5th \>34.8 ng/mL                               1.000                              
    4th \>28.4 ≤ 34.8 ng/mL                        2.648       0.942    7.445        0.065
    3rd \>23.1 ≤ 28.4 ng/mL                        2.201       0.750    6.457        0.151
    2nd \>17.7 ≤ 23.1 ng/mL                        3.917       1.473    10.419       0.006
    1st ≤17.7 ng/mL                                4.249       1.572    11.484       0.004

PTH: parathyroid hormone; CRP: C-reactive protein; HR: hazard ratio; CI, confidence interval; BMI: body mass index; RAS: renin-angiotensin system.

Discussion {#s0005}
==========

Several reasons underlie the presence of low serum 25(OH)D levels in CKD patients \[[@CIT0017]\]. Hypovitaminosis D is harmful and providing vitamin D supplements can be beneficial \[[@CIT0018]\]. There is disagreement in the literature regarding the benefits of vitamin D replacement therapy in patients with CKD who undergo HD, especially in relation to its effect on mortality \[[@CIT0019]\]. In addition, the 25(OH)D target level that is associated with the best prognoses for these patients remains unclear \[[@CIT0020]\]. This study's findings showed an association between the serum 25(OH)D concentration in summer and mortality in HD patients, and we determined that a serum 25(OH)D level ≤23.6 ng/mL in summer was associated with a higher mortality rate, which indicates a possible minimum level that should be verified in subsequent studies. Notably, this association persisted even after adjusting the model for the confounding variables in the Cox proportional hazards regression analysis.

Association was also shown between serum 25 (OH) D concentration in winter and with higher mortality. However, this occurred in different quintile levels (first quintile and third quintile), with serum levels of 25 (OH) *D* ≤ 17.5 ng/mL and serum levels of 25 (OH) *D* \> 21.5 -- ≤27.1 ng/mL. However, no increased risk of death was found with the second quintile. We have no explanation for this finding, and there was a lack of information about this in the literature. We cannot conclude that these discrepancies occurred by chance. Therefore, the number of measures of vitamin D possibly could explain this paradoxical result, in the winter period. Due to the small sample size of observations for each patient group when they were divided into subgroups, we considered that we may have suffered a loss of statistical power. Probably, if we had a larger sample size, we could have had homogeneous results. Therefore, this study must be repeated with a larger sample size. If these data were reproduced in other cases, it would deserve pathophysiological studies.

Accounting for vitamin D levels that were annually averaged can produce more robust and precise results because the number of observations could be increased. In this study, regardless of the seasonal levels, the average annual value of vitamin D in HD patients that was associated with all-cause mortality was ≤23.1 ng/mL. Values that were very close to this were found in the analysis in the summer period. Thus, if we had to dose vitamin D only once a year, it would be preferred that this should be done in the summer period, because of the association with mortality.

Patients with CKD have elevated levels of factors associated with inflammation. Cholecalciferol supplementation reduces inflammation and, subsequently, the C-reactive protein level \[[@CIT0021],[@CIT0022]\]. The findings from a randomized placebo-controlled clinical trial showed that cholecalciferol supplementation had an anti-inflammatory effect and it increased the expression of the intracellular vitamin D regulatory enzymes within lymphocytes in a uremic environment \[[@CIT0023]\]. In the present study, the association between vitamin D and mortality persisted, even after the model was adjusted for the C-reactive protein levels. Therefore, the influence on mortality was inherent to these variables.

Unlike the findings from other observational studies \[[@CIT0009],[@CIT0024]\], vitamin D was not associated with fatal cardiovascular events in this study; however, the number of these fatal events was small in this study, which may have contributed to the absence of an association. The findings from a systematic review of 13 randomized clinical trials that compared vitamin D supplementation with placebo, did not demonstrate that vitamin D supplementation modified the mortality or cardiovascular risk in patients with CKD \[[@CIT0025]\].

The presence of atherosclerotic disease is a risk factor for mortality, and the association between the 25(OH)D concentration and vascular calcification could explain this phenomenon. The findings from a small observational study showed that the serum 25(OH)D concentration was negatively associated with the degree of vascular calcification in patients with end-stage CKD, indicating that vitamin D could, paradoxically, inhibit calcification \[[@CIT0026]\].

In this study, the use of calcitriol during the first year of follow-up was not related to mortality; a result that differs from other studies' findings reported in the literature. One study's findings showed that treatment with calcitriol was associated with better survival among HD patients \[[@CIT0027]\]. The findings from a systematic review of 14 observational studies demonstrated that using calcitriol was associated with reduced mortality \[[@CIT0028]\]. However, these studies were prone to 'immortal time bias' \[[@CIT0029]\], which describes a spurious association between exposure to a given drug and better survival that occurs as a consequence of survivors having longer follow-up durations in which the drug can be prescribed, and, in fact, it is not that survival is better among the patients who receive the drug, rather than the patients who survive the longest receive the drug at some point. In the current study, the use of calcitriol was taken into account only when it was used during the first year of follow-up, specifically to avoid immortal time bias. Hence, even though there were no associations between calcitriol use and the outcomes, this variable was included in the multivariate analysis and, even after this adjustment, the association between the 25(OH)D concentration and mortality persisted.

This study's results should be considered in the context of its limitations. Given the inherent shortcomings associated with retrospective observational studies, this study's design should be considered a limitation. Importantly, while the study sample was representative of Brazilian people undergoing HD in relation to age and sex, it was not representative of the underlying disease, because arterial hypertension is the main cause of CKD according to the 2016 Brazilian Society of Nephrology's census \[[@CIT0030]\], but in this study, the main cause of CKD was diabetes mellitus. Another factor associated with the representativeness of this study's results was the high frequency of Caucasian participants. All of these differences reduce the external validity of this study's data, and they probably limit the generalizability of the data to the Brazilian population south of Botucatu; therefore, the data generated by this study should be validated in prospective multicenter clinical studies that involve several regions in Brazil.

Conclusion {#s0006}
==========

An association between serum vitamin D levels and mortality in HD patients was identified. Vitamin D levels ≤23.6 ng/mL in the summer were associated with higher all-cause mortality rates as levels of 21.5--≤27.1 ng/mL and ≤17.5 ng/mL in the winter were associated with higher all-cause mortality. Regardless of seasonal levels, the average annual value of vitamin D in HD patients that was associated with all-cause mortality was ≤23.1 ng/mL.

This study will encourage further work to assess whether the reference vitamin D level currently used in the general population is applicable to HD patients. An interventional study involving different vitamin D targets is needed to assess its impact on mortality. The current evaluation has direct implications regarding the target vitamin D level that should be sought with cholecalciferol replacement therapy in these patients.
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